Workflow
Data licensing agreements
icon
Search documents
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
Prnewswire· 2025-09-19 17:35
Core Viewpoint - Kuehn Law is investigating potential breaches of fiduciary duties by officers and directors of Tempus AI, Inc. regarding the company's representation as an AI firm despite limited revenue generation from AI solutions [1] Company Overview - Tempus AI primarily generates revenue from acquisitions, genomic testing, and data licensing agreements rather than from AI solutions [1] - The company has emphasized its relationship with AstraZeneca, citing it as a long-term customer and an example of secure and expanding data licensing agreements [1] Recent Developments - Tempus announced an expanding contract with AstraZeneca through a joint venture involving Pathos AI, indicating efforts to enhance revenue growth [1] - A joint venture with SoftBank was also announced, aimed at entering the Japanese market to drive revenue growth [1] - The acquisition of Ambry Genetics is highlighted, with claims of high revenue potential attributed to strong relationships with healthcare providers [1]
Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
GlobeNewswire News Room· 2025-06-13 19:00
Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged securities fraud, claiming the company misrepresented its AI capabilities and financial health to investors [1][4][5]. Company Overview - Tempus AI, Inc. is publicly traded on NASDAQ under the ticker symbol TEM and has been accused of branding itself as an AI company despite limited revenue generation from AI solutions [4]. - The company primarily generates revenue through acquisitions, genomic testing, and data licensing agreements [4]. Allegations and Concerns - The lawsuit alleges that Tempus misled investors about the security and expansion of its data licensing agreements, particularly with AstraZeneca, and claimed high revenue potential from its acquisition of Ambry Genetics [4]. - A report by Spruce Point Capital Management raised concerns about Tempus' management practices, overstated AI capabilities, and aggressive accounting [5]. - Specific issues highlighted include the CEO's history of cashing out before public shareholders incur losses, connections to troubled companies, and recent revisions in financial guidance indicating weaknesses in core operations [5]. Financial Impact - Following the release of the Spruce Point Report, Tempus' stock price dropped by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [6]. Legal Information - Investors who purchased Tempus stock between August 6, 2024, and May 27, 2025, are eligible to participate in the class action lawsuit, with a deadline to request lead plaintiff status by August 12, 2025 [6]. Legal Representation - Shamis & Gentile, P.A. is representing the impacted investors and has a history of recovering over $1 billion for consumers affected by securities fraud [7].